Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

Enamine Extends Collaboration with UkrOrgSynthesis

Published: Thursday, April 19, 2012
Last Updated: Thursday, April 19, 2012
Bookmark and Share
Collaboration offers world's largest collection of chemical building blocks.

Enamine Ltd. and UkrOrgSynthesis Ltd have announced they have signed a collaboration agreement to offer chemical building blocks to the drug discovery industry.

By combining their catalogues, the companies become the largest global manufacturer and seller of building blocks, with 60,000 products available from stock for immediate delivery and an array of ca. 8 million tangible building blocks deliverable at fixed prices within 4-6 weeks, with synthetic success rate of 80%.

According to the terms of the agreement, UORSY products are now obtainable through Enamine, and up-to-date catalogues of in-stock and tangible building blocks from both companies are available from both Enamine and UORSY.

Enamine is now able to act as a single point of contact for requests from both catalogues, at no extra cost to customers.

Enamine and UORSY have received many requests over the years for building blocks from both in-stock and tangible collections from a wide range of pharmaceutical, agrochemical, cosmetic, and nutraceutical companies, and academic research institutions, in a continuously growing trend.

Michael Bossert, Business Development Director, said “We are confident that the collaboration extension will enable us to offer enhanced customer service, and improve the day-to-day selection, ordering and purchasing process for clients. We hope that this will result in a significant increase in market share for both Enamine and UORSY.”

He continued, “Enamine and UORSY have been working together in the design of building blocks for several years, and the extension of the collaboration for provision of logistical support from Enamine is a natural step in the business relationship.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
Designing Drugs with a Whole New Toolbox
Researchers develop methods to design small, targeted proteins with shapes not found in nature.
Small Molecules Lead to a Big Change in Reaction Outcomes
Scientists have changed the behaviour of a group of molecules involved in carbon-oxygen bond synthesis.
Targeting Fat to Treat Cancer
Researchers develop novel cancer treatment that halts fat synthesis in cells, stunting tumors.
Hyperstable Peptides for 'On-Demand' Drugs
These small molecules can fold into different conformations that could allow for greater flexibility in precision drug design
Drug Leads Identified to Combat Heart Disease
Using three supercomputers, researchers surveyed protein structures through accelerated molecular dynamics.
Accelerating the Path to Molecules for Medicine
Researchers convert carbon-hydrogen bonds into nitriles - converting organic molecules into components of medicines.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos